Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $49,278.63 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 2,631 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $18.73, for a total transaction of $49,278.63. Following the completion of the sale, the chief executive officer owned 339,392 shares of the company’s stock, valued at approximately $6,356,812.16. The trade was a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Claire Mazumdar also recently made the following trade(s):

• On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.75, for a total transaction of $71,568.75.
• On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.74, for a total transaction of $33,469.64.

Bicara Therapeutics Stock Down 0.2%

Shares of BCAX opened at $18.47 on Monday. Bicara Therapeutics Inc. has a fifty-two week low of $7.80 and a fifty-two week high of $19.71. The company’s fifty day moving average is $16.47 and its two-hundred day moving average is $15.82. The firm has a market cap of $1.01 billion, a PE ratio of -8.25 and a beta of -0.78.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on BCAX shares. Mizuho upgraded Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. BTIG Research restated a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Citigroup started coverage on Bicara Therapeutics in a research note on Thursday, January 29th. They issued an “outperform” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Seven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $28.33.

Institutional Trading of Bicara Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Bleakley Financial Group LLC acquired a new position in shares of Bicara Therapeutics during the third quarter worth about $481,000. Skandinaviska Enskilda Banken AB publ boosted its holdings in Bicara Therapeutics by 160.9% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 99,236 shares of the company’s stock worth $922,000 after acquiring an additional 61,201 shares during the period. Artisan Partners Limited Partnership acquired a new stake in Bicara Therapeutics in the second quarter valued at approximately $3,742,000. Schroder Investment Management Group grew its position in Bicara Therapeutics by 921.0% in the second quarter. Schroder Investment Management Group now owns 425,341 shares of the company’s stock valued at $3,951,000 after acquiring an additional 383,681 shares in the last quarter. Finally, SCS Capital Management LLC purchased a new stake in shares of Bicara Therapeutics during the second quarter valued at approximately $496,000.

Bicara Therapeutics News Roundup

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Several institutional investors increased or initiated positions in BCAX recently (e.g., Woodline, Geode, Nan Fung, AQR), which supports demand from professional managers and can offset selling pressure. Read More.
• Positive Sentiment: Analyst coverage remains largely favorable — multiple firms maintain Buy/Outperform ratings and the consensus price target sits well above the current price, providing a bullish backdrop for longer‑term holders. Read More.
• Neutral Sentiment: The company announced an inducement equity grant under Nasdaq Rule 5635(c)(4) for a new hire — routine for growth‑stage biotech but can add modest dilution expectations. Read More.
• Neutral Sentiment: Published short‑interest entries for early March report “large increases” but show 0 shares/NaN changes — the data appears erroneous and does not provide reliable evidence of increased shorting. (No actionable short‑sale signal.)
• Negative Sentiment: CFO Ivan Hyep sold stock across March 3–4 (totaling 16,518 shares across recent sales), reducing his stake; sizable CFO sales can sap near‑term sentiment. Read More.
• Negative Sentiment: COO Ryan Cohlhepp sold 17,392 shares on March 3 (~7.8% reduction in his holding). Executive selling at this scale may be viewed as liquidity‑taking and can pressure the share price. Read More.
• Negative Sentiment: Insider David Raben sold ~16,500 shares in two transactions (including a 16,300‑share sale), representing a large reduction in one filing; founder/executive selling is commonly interpreted negatively by the market. Read More.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.